SCHEMBL1115469

SCHEMBL1115469

Cc1ccc(C(=O)C2CNCCN2C(=O)OC(C)(C)C)cc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PARP1 P09874 1/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NR1H2 P55055 2/20 0.38
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD11B1 P28845 2/20 0.36
GPR119 Q8TDV5 2/20 0.36
MC4R P32245 1/20 0.35
MC5R P33032 1/20 0.35
NR1H3 Q13133 1/20 0.35
UCHL1 P09936 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28978028 0.81 MAPK1 (0.43) PARP1NPC1GPR119MC4RMC5R
SCHEMBL28067177 0.79 GPR119 (0.47) PARP1NPC1GPR119MC4RMC5R
SCHEMBL17560446 0.79 PARP1 (0.41) LMNANPSR1PARP1NPC1GPR119
SCHEMBL30740797 0.78 PARP1 (0.38) LMNANPSR1PARP1NPC1POLB
SCHEMBL31218680 0.75 DDB1 (0.39) PARP1NPC1NR1H2MC4RMC5R
SCHEMBL8554593 0.74 PARP1 (0.43) LMNANPSR1PARP1NPC1NR1H2
SCHEMBL17560433 0.74 PARP1 (0.43) LMNANPSR1PARP1NPC1NR1H2
SCHEMBL8554343 0.74 PARP1 (0.43) LMNANPSR1PARP1NPC1NR1H2
SCHEMBL990488 0.73 CA1 (0.40) HSD11B1L3MBTL1
SCHEMBL29072017 0.73 PARP1 (0.39) LMNANPSR1PARP1NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606265-B1 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NOVARTIS AG (CH) 2011-02-02 EP disclosed